Aadi Bioscience to Announce Q1 2024 Results and Corporate Update

Aadi Bioscience, Inc., a prominent commercial-stage precision oncology company, is set to host a conference call and live webcast on May 8, 2024, at 8:30 am EDT (5:30 am PDT). This event aims to disclose the company's first quarter financial results for 2024 and present recent corporate developments.

For those interested in participating, the live webcast can be accessed on the "Investors & News" section of Aadi Bioscience's website. Telephone participants are required to register in advance through a provided registration link. After registration, participants will receive detailed instructions via email on how to join the call, including a dial-in number and a unique passcode. For those unable to join the live event, a replay of the conference call and webcast will be available on the company's website for at least 30 days.

Aadi Bioscience is dedicated to developing and commercializing therapies specifically targeted at cancers with alterations in the mTOR pathway, which is a crucial regulator of cell growth and cancer progression. The company leverages its unique approach by combining nanoparticle albumin-bound (nab) technology with sirolimus, a potent mTOR inhibitor. Aadi Bioscience has successfully obtained FDA approval for its product FYARRO®, which is used to treat adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).

The company's ongoing research includes the exploration of nab-sirolimus in the PRECISION1 trial, a Phase 2 tumor-agnostic study aimed at mTOR inhibitor-naïve malignant solid tumors with TSC1 or TSC2 inactivating alterations. Additionally, Aadi is conducting two single-indication Phase 2 trials to investigate nab-sirolimus combined with letrozole for the treatment of neuroendocrine tumors (NETs) and advanced or recurrent endometrioid-type endometrial cancer (EEC), both of which are challenging mTOR-driven cancers.

Aadi Bioscience continues to expand its development pipeline and remains focused on unlocking the full potential of mTOR inhibition to provide effective therapies for patients with difficult-to-treat cancers.